PMID: 7085003Jan 1, 1982Paper

Action of a new non-steroid anti-inflammatory drug, carprofen (Ro 20-5720) on activation of the complement system: an in vitro research

International Journal of Tissue Reactions
A AuteriaT Di Perri

Abstract

Carprofen (Ro 20-5720), DL-6-chloro-alpha-methyl-carbazole-2-acetic acid, is a new non-steroid anti-inflammatory drug. We have studied the possible in vitro interference of the drug with the activation of human complement system. Carprofen exerts a constant inhibitory action of immunohaemolysis at a concentration of 4.5 X 10(-4)M. At the same concentration the drug is able to prevent the activation of the alternate pathway induced by insulin. Its specific site of action is on C1 and C3 components activation, according to the inhibiting activity on both classic and alternate pathway. However at a lower dosage (7.5 X 10(-6)M) carprofen is able to display an inducing action on the alternate pathway, thus confirming the complex in vitro interferences of the drug with the complement system.

Related Concepts

Ro 205720
Anti-Inflammatory Agents
Carbazoles
Complement Activation
Complement Pathway, Alternative
Complement Pathway, Classical
Complement C1r Protease Inhibitor Proteins
Complement C3 precursor
Dose-Response Relationship, Drug
Medicinal Plants Testing, Preclinical

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.